MARKET

BCAB

BCAB

Bioatla, Inc.
NASDAQ
0.1700
+0.0119
+7.53%
Closed 19:13 03/26 EDT
OPEN
0.1543
PREV CLOSE
0.1581
HIGH
0.1700
LOW
0.1500
VOLUME
747.83K
TURNOVER
0
52 WEEK HIGH
1.430
52 WEEK LOW
0.1300
MARKET CAP
14.08M
P/E (TTM)
-0.1476
1D
5D
1M
3M
1Y
5Y
1D
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/26/26
TipRanks · 19h ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/25/26
TipRanks · 1d ago
VTI Sees $2B in Net Flows – Why Investors Are Pouring Into This Vanguard ETF
TipRanks · 2d ago
BioAtla Shareholders Approve Merger and Share Consolidation
TipRanks · 3d ago
Why Is Vanguard Total Stock Market ETF (VTI) Up Today, 03/23/26?
TipRanks · 3d ago
Weekly Report: what happened at BCAB last week (0316-0320)?
Weekly Report · 3d ago
Why Is Vanguard Total Stock Market ETF (VTI) Down Today, 3/20/26?
TipRanks · 6d ago
VTI Sees $1B Inflows as Vanguard ETF Gains Momentum — 3/19/26
TipRanks · 03/19 14:53
More
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Webull offers Bioatla Inc stock information, including NASDAQ: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.